| P2093 | author name string | Shidong Jia | |
| | Dena Marrinucci | |
| | Liangxuan Zhang | |
| | Natalie L Prigozhina | |
| | Sharon Beasley | |
| | Florence Y Lee | |
| | Shoji Ikeda | |
| | Renee Higgins | |
| P2860 | cites work | Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma | Q39780696 |
| | Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation | Q40904015 |
| | Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma | Q41073565 |
| | Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications. | Q47901564 |
| | Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. | Q52868194 |
| | Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. | Q55235329 |
| | Multiple Myeloma | Q56453538 |
| | Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | Q60203403 |
| | Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma | Q71249373 |
| | Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen | Q73309773 |
| | Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma | Q83128050 |
| | Characterization of clonogenic multiple myeloma cells | Q24610291 |
| | High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis | Q24634121 |
| | Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers | Q24634168 |
| | Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine | Q26825186 |
| | The promise of circulating tumor cell analysis in cancer management | Q27022113 |
| | New criteria for response assessment: role of minimal residual disease in multiple myeloma | Q27027512 |
| | Mutational landscape and significance across 12 major cancer types | Q28300353 |
| | Clonal evolution in cancer | Q29547696 |
| | The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 |
| | Bortezomib in multiple myeloma: systematic review and clinical considerations | Q33982728 |
| | PI3K/p110{delta} is a novel therapeutic target in multiple myeloma | Q34124937 |
| | Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Q34166574 |
| | Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 |
| | Spatial and temporal diversity in genomic instability processes defines lung cancer evolution | Q34442770 |
| | Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials | Q34973992 |
| | Tumor clone dynamics in lethal prostate cancer | Q35575930 |
| | Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma | Q35848236 |
| | Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system | Q35849614 |
| | An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma | Q35868171 |
| | Conventional diagnostics in multiple myeloma | Q36500714 |
| | Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells | Q36513782 |
| | Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide | Q36640589 |
| | Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout | Q36785501 |
| | Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma | Q36868120 |
| | VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma | Q36878944 |
| | Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo | Q37377754 |
| | Immunophenotyping in multiple myeloma and related plasma cell disorders | Q37812870 |
| | Association of response endpoints with survival outcomes in multiple myeloma | Q38122624 |
| | Role of consolidation/maintenance therapy in multiple myeloma. | Q38167435 |
| | Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. | Q38305991 |
| | The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma | Q39210830 |
| | Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma | Q39277209 |
| | Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma | Q39465626 |
| | Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention | Q39548450 |
| P304 | page(s) | 10 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Journal of Circulating Biomarkers | Q50814778 |
| P1476 | title | Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma. | |
| P478 | volume | 5 | |